<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033318</url>
  </required_header>
  <id_info>
    <org_study_id>1809-001</org_study_id>
    <secondary_id>MK1809-001</secondary_id>
    <secondary_id>2009_703</secondary_id>
    <nct_id>NCT01033318</nct_id>
  </id_info>
  <brief_title>A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify at least one safe and well tolerated dose of MK1809&#xD;
      that has similar pharmacokinetic qualities as 100 mg losartan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2007</start_date>
  <completion_date type="Actual">June 19, 2008</completion_date>
  <primary_completion_date type="Actual">June 19, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Area under the plasma concentration (AUC) versus time curve in healthy adult male subjects in the fasted state</measure>
    <time_frame>Through 32 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Trough plasma concentration in healthy adult male subjects in the fasted state</measure>
    <time_frame>24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Safety and tolerability of rising single oral doses of MK1809 in adult hypertensive patients based on an assessment of clinical and laboratory adverse experiences</measure>
    <time_frame>Duration of study and up to 14 days after administration of the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration (AUC) versus time curve resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)</measure>
    <time_frame>24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum concentration of drug in the plasma (Cmax) resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)</measure>
    <time_frame>Through 32 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of clinical and laboratory adverse experiences (AEs) to assess safety and tolerability</measure>
    <time_frame>Duration of study and up to 14 days after administration of the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area under the plasma concentration (AUC) versus time curve of the E3174 metabolite</measure>
    <time_frame>Through 32 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Trough plasma concentration of the E3174 metabolite</measure>
    <time_frame>Through 32 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part 1 A-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel A; Sequence 1:&#xD;
2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 A-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel A; Sequence 2:&#xD;
Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 A-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 A-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 A-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel A; Sequence 5:&#xD;
Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel B; Sequence 1:&#xD;
5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel B; Sequence 2:&#xD;
5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel B; Sequence 3:&#xD;
5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel B; Sequence 4:&#xD;
Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1; Panel B; Sequence 5:&#xD;
Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 C-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2; Panel C; Sequence 1:&#xD;
50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 C-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2; Panel C; Sequence 2:&#xD;
50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 C-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2; Panel C; Sequence 3:&#xD;
Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 C-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2; Panel C; Sequence 4:&#xD;
50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 C-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2; Panel C; Sequence 5:&#xD;
Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1809</intervention_name>
    <description>single oral doses of MK1809</description>
    <arm_group_label>Part 1 A-1</arm_group_label>
    <arm_group_label>Part 1 A-2</arm_group_label>
    <arm_group_label>Part 1 A-3</arm_group_label>
    <arm_group_label>Part 1 A-4</arm_group_label>
    <arm_group_label>Part 1 A-5</arm_group_label>
    <arm_group_label>Part 1 B-1</arm_group_label>
    <arm_group_label>Part 1 B-2</arm_group_label>
    <arm_group_label>Part 1 B-3</arm_group_label>
    <arm_group_label>Part 1 B-4</arm_group_label>
    <arm_group_label>Part 1 B-5</arm_group_label>
    <arm_group_label>Part 2 C-1</arm_group_label>
    <arm_group_label>Part 2 C-2</arm_group_label>
    <arm_group_label>Part 2 C-3</arm_group_label>
    <arm_group_label>Part 2 C-4</arm_group_label>
    <arm_group_label>Part 2 C-5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Losartan</intervention_name>
    <description>single oral doses of 100 mg Losartan</description>
    <arm_group_label>Part 1 A-1</arm_group_label>
    <arm_group_label>Part 1 A-2</arm_group_label>
    <arm_group_label>Part 1 A-3</arm_group_label>
    <arm_group_label>Part 1 A-4</arm_group_label>
    <arm_group_label>Part 1 A-5</arm_group_label>
    <arm_group_label>Part 1 B-2</arm_group_label>
    <arm_group_label>Part 1 B-3</arm_group_label>
    <arm_group_label>Part 1 B-4</arm_group_label>
    <arm_group_label>Part 1 B-5</arm_group_label>
    <arm_group_label>Part 2 C-1</arm_group_label>
    <arm_group_label>Part 2 C-2</arm_group_label>
    <arm_group_label>Part 2 C-3</arm_group_label>
    <arm_group_label>Part 2 C-4</arm_group_label>
    <arm_group_label>Part 2 C-5</arm_group_label>
    <other_name>Losartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo to MK1809</description>
    <arm_group_label>Part 1 A-1</arm_group_label>
    <arm_group_label>Part 1 A-2</arm_group_label>
    <arm_group_label>Part 1 A-3</arm_group_label>
    <arm_group_label>Part 1 A-4</arm_group_label>
    <arm_group_label>Part 1 A-5</arm_group_label>
    <arm_group_label>Part 1 B-1</arm_group_label>
    <arm_group_label>Part 1 B-2</arm_group_label>
    <arm_group_label>Part 1 B-4</arm_group_label>
    <arm_group_label>Part 1 B-5</arm_group_label>
    <arm_group_label>Part 2 C-1</arm_group_label>
    <arm_group_label>Part 2 C-2</arm_group_label>
    <arm_group_label>Part 2 C-3</arm_group_label>
    <arm_group_label>Part 2 C-4</arm_group_label>
    <arm_group_label>Part 2 C-5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Nonsmoker for at least 6 months&#xD;
&#xD;
          -  Body Mass Index (BMI) less than or equal to 29 kg/m2&#xD;
&#xD;
          -  In overall good health&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2&#xD;
&#xD;
          -  In overall good health (patients with hypertension and/or hyperlipidemia are accepted)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  History of any cardiovascular disease or any clinically significant family history of&#xD;
             cardiac arrhythmias or conduction abnormalities at an age less than 60 years&#xD;
&#xD;
          -  History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic,&#xD;
             renal or genitourinary disease/disorder&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Clinically significant history of a neurological disorder (includes epilepsy,stroke,&#xD;
             transient ischemic attack, classic migraines)&#xD;
&#xD;
          -  Active or history of a psychiatric disorder (includes depression, bipolar disorder,&#xD;
             schizophrenia, anxiety)&#xD;
&#xD;
          -  History of asthma, severe wheezing, COPD, or other pulmonary disease&#xD;
&#xD;
          -  Individual or family history of bleeding or hemorrhagic diathesis, or bleeding&#xD;
             difficulties&#xD;
&#xD;
          -  Major surgery, donated blood or participated in another investigational drug(s) trial&#xD;
             within 30 days&#xD;
&#xD;
          -  Illicit drug use (including recreational); or history of drug or alcohol abuse (within&#xD;
             2 years)&#xD;
&#xD;
          -  Nitrate therapy within 4 weeks&#xD;
&#xD;
          -  History of significant drug allergy or history of food allergies&#xD;
&#xD;
        Part 2&#xD;
&#xD;
          -  History of any clinically significant cardiac or cardiovascular disease (other than&#xD;
             hypertension)&#xD;
&#xD;
          -  History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic,&#xD;
             renal or genitourinary disease/disorder&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  History of a neurological disorder (includes epilepsy,stroke, transient ischemic&#xD;
             attack, classic migraines)&#xD;
&#xD;
          -  Active or history of a psychiatric disorder (includes depression, bipolar disorder,&#xD;
             schizophrenia, anxiety)&#xD;
&#xD;
          -  History of asthma, severe wheezing, COPD, or other pulmonary disease&#xD;
&#xD;
          -  Individual or family history of bleeding or hemorrhagic diathesis, or bleeding&#xD;
             difficulties&#xD;
&#xD;
          -  Illicit drug use (including recreational); or history of drug or alcohol abuse (within&#xD;
             2 years)&#xD;
&#xD;
          -  Surgery, significant blood loss, donated blood, or participated in another&#xD;
             investigational drug(s) trial within 30 days&#xD;
&#xD;
          -  Nitrate therapy within 4 weeks&#xD;
&#xD;
          -  History of significant drug allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

